

Red Cell Life Span (RBC) in Chronic Kidney Disease (CKD)

ACTRN12610000145000

Status	RECRUITING
Sponsor	University of Otago
Enrollment	56 participants

Plain Language Summary

This study is measuring how long red blood cells survive in people with chronic kidney disease (CKD). Red blood cells normally live about 120 days, but in people with kidney disease they may not last as long. Researchers will track this using a safe radioactive tag applied to the blood cells, and will also look at how this affects a common diabetes test called HbA1c.

You may be eligible if:

- You are 18 years of age or older
- You have moderate CKD (stage III, with a filtration rate of 30–59 mL/min) OR you are on haemodialysis or peritoneal dialysis for at least 2 months OR you have diabetes with normal kidney function OR you are a healthy control

You may NOT be eligible if:

- You are on dialysis but not receiving erythropoietin (EPO) or iron treatment
- Your haemoglobin (blood count) is outside the target range (110–130 g/L)
- You have had recent blood loss or a blood transfusion
- You have an active inflammatory illness
- You have a solid organ cancer
- You have unstable blood sugar control
- You are pregnant

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Patients of at least 18 years of age and on dialysis at least for 2 months haemodialysis (HD) and peritoneal dialysis (PD) will be invited to participate in this study, stable subjects with moderate CKD (stage III, defined as a glomerular filtration rate (GFR) (30-59 ml/min), subjects with diabetes mellitus with normal renal function and healthy controls

Exclusion (1)

- HD and PD patients not on erythropoietin and/or iron supplement therapy. Haemoglobin concentrations not within the recommended target range (Hb: 110-130 g/l). Evidence of recent blood loss and or recent blood transfusion. Intercurrent inflammatory illness or drugs which may influence bone marrow function. Solid organ malignancy. Unstable glycaemic control. Pregnancy. Women of child bearing potential will be advised to practise an acceptable form of contraception for the duration of the study.

Locations (1 total)

New Zealand

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12610000145000>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.